Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NKGN

NKGen Biotech Inc

Dec 13 • 04:00PM ET

0.4998

Dollar change +0.0050
Percentage change 1.01	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP FATE BLUE EDIT ALLO NTLA ZLAB BEAM SGMO CLLS

| Held by: VTI IWC VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.92	Insider Own	48.77%	Shs Outstand	25.77M	Perf Week	14.01%
Market Cap	17.94M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	18.20M	Perf Month	102.35%
Income	-88.25M	PEG	-	EPS next Q	-	Inst Own	10.57%	Short Float	4.79%	Perf Quarter	-32.91%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	8.07%	Short Ratio	0.64	Perf Half Y	-62.98%
Book/sh	-2.29	P/B	-	EPS next Y	-	ROA	-196.21%	Short Interest	0.87M	Perf Year	-86.38%
Cash/sh	0.01	P/C	54.36	EPS next 5Y	-	ROE	-118.66%	52W Range	0.20 - 4.06	Perf YTD	-81.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-87.69%	Beta	0.75
Dividend TTM	-	Quick Ratio	0.02	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	146.69%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	0.02	EPS Y/Y TTM	-2481.33%	Oper. Margin	-	RSI (14)	60.55	Volatility	14.17% 17.96%
Employees	63	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-511.76%	Payout	-	Rel Volume	0.15	Prev Close	0.49
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.36M	Price	0.50
SMA20	21.15%	SMA50	39.00%	SMA200	-50.29%	Trades		Volume	202,514	Change	1.01%

Dec-02-24 04:05PM	NKGen Biotech Selected as Stalking Horse Bidder for NKMax (GlobeNewswire) +9.98% +10.71%
Nov-26-24 04:15PM	NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel (GlobeNewswire) +14.72% -10.72%
Oct-29-24 08:05AM	NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -11.17%
Oct-15-24 08:05AM	NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) (GlobeNewswire) -6.54%
Oct-08-24 08:05AM	NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -8.13%
08:05AM	Loading…
Sep-12-24 08:05AM	NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial (GlobeNewswire) +11.62%
Sep-03-24 08:05AM	NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-22-24 04:40PM	NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report (GlobeNewswire) +7.37%
Jul-30-24 08:05AM	NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference (GlobeNewswire) -14.40%
Jul-18-24 08:05AM	NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference (GlobeNewswire) +18.59%
Jul-15-24 08:05AM	NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors (GlobeNewswire)
Jun-12-24 01:05PM	NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 (GlobeNewswire) -8.51%
Jun-03-24 08:05AM	NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 (GlobeNewswire) -6.59%
May-23-24 05:05PM	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -23.66%
May-21-24 09:53AM	NKGN Stock Earnings: NKGen Biotech Reported Results for Q1 2024 (InvestorPlace)
11:41AM	Loading…
May-20-24 11:41AM	NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today (InvestorPlace) +52.68%
08:05AM	NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease (GlobeNewswire)
May-16-24 08:05AM	NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition (GlobeNewswire)
Apr-29-24 08:00AM	NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinsons Disease (GlobeNewswire)
Apr-25-24 04:05PM	NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) +15.79% -18.69%
Apr-24-24 04:45PM	NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.57%
Apr-18-24 04:05PM	NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) -16.50% +28.60%
Apr-16-24 11:53PM	NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023 (InvestorPlace) -14.88%
Apr-11-24 08:05AM	NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs (GlobeNewswire)
Mar-25-24 04:05PM	NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire) -6.90% -11.11%
Mar-06-24 07:52AM	Why Is NKGen Biotech (NKGN) Stock Up 62% Today? (InvestorPlace) +112.30%
Mar-04-24 08:00AM	NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire)
Feb-07-24 08:57AM	Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies (News Direct)
Dec-29-23 07:30AM	NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial (News Direct) -10.42%
Dec-28-23 04:05PM	NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease (GlobeNewswire) -7.53%
08:00AM	Loading…
Dec-27-23 08:00AM	NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease (GlobeNewswire) +17.73%
Nov-14-23 04:48PM	NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-23 08:00AM	NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +8.00%
Oct-24-23 10:53AM	NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimers Disease Treatment. (News Direct) +16.16%
08:00AM	NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimers Disease (GlobeNewswire)
Oct-19-23 08:00AM	NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Oct-17-23 08:00AM	NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023 (GlobeNewswire)
Oct-11-23 08:00AM	NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023 (GlobeNewswire)

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKGN

NKGen Biotech Inc

Upgrade your FINVIZ experience